In several cancers, such as breast, colorectal and gastric cancers, the mis-localization of RUNX3 to the cytoplasm is thought to result in tumor progression; however, in other cancers including NSCLC, it was found that the loss of RUNX3 expression through posttranslational modification leads to tumor progression [44]. Here, RUNX3 is linked to cancer.